Suppr超能文献

多重耐药性胃肠道感染的非抗生素疗法:益生菌、天然化合物和噬菌体的应用概述

Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.

作者信息

Oliveira Manuela, Madureira-Carvalho Áurea, Dinis-Oliveira Ricardo Jorge, Dias da Silva Diana

机构信息

Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.

Applied Molecular Biosciences Unit (UCIBIO), Forensics and Biomedical Sciences Research Laboratory, University Institute of Health Sciences, One Health Toxicology Research Unit (1H-TOXRUN), Instituto Universitário de Ciências da Saúde da Cooperativa de Ensino Superior Politécnico e Universitário (IUCSCESPU), Gandra, Portugal.

出版信息

Front Antibiot. 2025 May 6;4:1554061. doi: 10.3389/frabi.2025.1554061. eCollection 2025.

Abstract

The worldwide increasing frequency and severity of multidrug-resistant gastrointestinal (MDR-GI) infections not only raises awareness of the debilities of conventional antibiotic treatments but also highlights the demand for alternative interventions. One of these alternatives is probiotics, harmless bacteria that compete with pathogenic species, which have been considered beneficial due to their therapeutic potential since they strengthen the mucosal barrier and modulate the host immune response. Other natural compounds (e.g., polyphenols, flavonoids, and essential oils) present diverse antimicrobial mechanisms, which are promising alternatives to mitigate resistant pathogens. Finally, bacteriophages, viruses that target specific bacteria, constitute a precise approach in which MDR bacteria are lysed or disrupted by the biofilms formed during colonization without compromising the normal gut microbiome. Therefore, the present manuscript provides an integrated perspective on alternative non-antibiotic therapies to manage MDR-GI infections; for this purpose, it covers aspects such as their action mechanisms, current clinical applications, and the challenges that limit their broader application in clinical practice. The potential of combining these approaches or personalizing infection treatments adjusted to patients' microbiome profiles is also discussed, aiming to enhance efficacy and reduce resistance risks. Finally, the importance of continued research and development to optimize these alternatives is also debated, addressing aspects such as the need to surpass regulatory barriers and conducting large-scale clinical trials to establish the safety and efficacy of these non-antibiotic alternatives. This overview of the current knowledge contributes to the ongoing efforts to develop sustainable strategies to combat MDR-GI infections and reduce the global burden of antibiotic resistance.

摘要

全球范围内多重耐药性胃肠道(MDR - GI)感染的频率和严重程度不断增加,这不仅提高了人们对传统抗生素治疗缺陷的认识,也凸显了对替代干预措施的需求。其中一种替代方法是益生菌,即与致病菌种竞争的无害细菌,由于它们具有治疗潜力,能够增强黏膜屏障并调节宿主免疫反应,因此一直被认为是有益的。其他天然化合物(如多酚、黄酮类化合物和精油)具有多种抗菌机制,是减轻耐药病原体的有前景的替代物。最后,噬菌体,即靶向特定细菌的病毒,构成了一种精确的方法,在这种方法中,多重耐药细菌在定植过程中形成的生物膜将其裂解或破坏,而不会损害正常的肠道微生物群。因此,本手稿提供了关于管理MDR - GI感染的替代非抗生素疗法的综合观点;为此,它涵盖了诸如其作用机制、当前临床应用以及限制其在临床实践中更广泛应用的挑战等方面。还讨论了将这些方法结合起来或根据患者的微生物组概况个性化感染治疗的潜力,旨在提高疗效并降低耐药风险。最后,还讨论了持续研发以优化这些替代方法的重要性,涉及需要克服监管障碍以及进行大规模临床试验以确定这些非抗生素替代物的安全性和有效性等方面。对当前知识的这一概述有助于为制定可持续战略以对抗MDR - GI感染和减轻全球抗生素耐药负担的持续努力做出贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7f5/12089134/8a9e295f7248/frabi-04-1554061-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验